Circulating CD71+ red blood cells (RBCs) have been reported to play an immunomodulatory role in vivo, which may contribute to adverse donor–recipient sex‐mismatched transfusion outcomes. However, it is not clear… Click to show full abstract
Circulating CD71+ red blood cells (RBCs) have been reported to play an immunomodulatory role in vivo, which may contribute to adverse donor–recipient sex‐mismatched transfusion outcomes. However, it is not clear how CD71+ RBC quantity in red cell concentrates (RCCs) is affected by manufacturing methods and donor factors such as donor sex, donor age, pre‐donation hemoglobin (Hb), venous Hb (Hbv) levels, and donation frequency.
               
Click one of the above tabs to view related content.